Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences, Ono Pharmaceutical Ink Cancer Drug Development Collaboration

NEW YORK – Caris Life Sciences and Ono Pharmaceutical said Thursday that they have entered a strategic collaboration using Caris' molecular profiling technologies across several studies of investigational targeted and immune-based cancer therapies.

Under the terms of the agreement, Caris will provide its suite of next-generation sequencing services, including its comprehensive liquid biopsy assay, which assesses 22,000 genes in both DNA and RNA, to aid in the development of therapies in areas of unmet need.

According to the Osaka, Japan-based pharma firm, the collaboration will start with one initial Phase III trial, with additional targets to be determined later.

"Collaborating with Caris gives us the opportunity to utilize world-class advanced technologies to improve our novel drug development capabilities," Kiyoaki Idemitsu, executive officer and executive director of clinical development at Ono, said in a statement.

Financial terms of the deal were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.